This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): atovaquone and proguanil hydrochloride
Description: The constituents of Malarone, atovaquone and proguanil hydrochloride, interfere with 2 different pathways involved in ATP and the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport, and in Plasmodium species, a major target appears to be the cytochrome bc1 complex (Complex III). Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a dihydrofolate reductase inhibitor. Inhibition of dihydrofolate reductase in the malaria parasite disrupts deoxythymidylate synthesis.
Pink Sheet GSK Malarone safety profile
Additional information available to subscribers only: